<?xml version="1.0" encoding="UTF-8"?>
<ref id="B1-jcm-09-01909">
 <label>1.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Nabavi</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Habtemariam</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Clementi</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Berindan-Neagoe</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Cismaru</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Rasekhian</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Banach</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Izadi</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Bagheri</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Bagheri</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Lessons learned from SARS-CoV and MERS-CoV: FDA-approved abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2</article-title>
  <source>Arch. Med. Sci.</source>
  <year>2020</year>
  <volume>16</volume>
  <fpage>519</fpage>
  <lpage>521</lpage>
  <pub-id pub-id-type="doi">10.5114/aoms.2020.94504</pub-id>
  <pub-id pub-id-type="pmid">32399097</pub-id>
 </element-citation>
</ref>
